Cryoport, Inc. (CYRX)

$13.46

+0.26

(+1.97%)▲

Market is closed - opens 7 PM, 10 May 2024

Insights on Cryoport, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 56.15M → 57.26M (in $), with an average increase of 1.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -13.26M → -62.38M (in $), with an average decrease of 370.2% per quarter

  • Vs FDX

    In the last 1 year, Fedex Corporation has given 12.9% return, outperforming this stock by 52.7%

  • Vs EXPD

    In the last 3 years, Cryoport, Inc. has experienced a drawdown of -79.1%, however Expeditors Intl. Of Washington Inc. resisted the overall trend and outperformed by 61.1%

Performance

  • $12.95
    $13.50
    $13.46
    downward going graph

    3.79%

    Downside

    Day's Volatility :4.07%

    Upside

    0.3%

    downward going graph
  • $9.00
    $23.50
    $13.46
    downward going graph

    33.14%

    Downside

    52 Weeks Volatility :61.7%

    Upside

    42.72%

    downward going graph

Returns

PeriodCryoport, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-16.93%
-1.3%
0.0%
6 Months
16.81%
13.2%
0.0%
1 Year
-39.78%
7.3%
1.1%
3 Years
-75.75%
14.5%
-22.1%

Highlights

Market Capitalization
797.9M
Book Value
$9.45
Earnings Per Share (EPS)
-2.21
PEG Ratio
0.0
Wall Street Target Price
18.33
Profit Margin
-42.69%
Operating Margin TTM
-34.34%
Return On Assets TTM
-3.67%
Return On Equity TTM
-19.06%
Revenue TTM
233.3M
Revenue Per Share TTM
4.79
Quarterly Revenue Growth YOY
-5.1%
Gross Profit TTM
103.9M
EBITDA
-31.2M
Diluted Eps TTM
-2.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.3
EPS Estimate Next Year
-1.0
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    62%Buy
    37%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Cryoport, Inc.(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
6
6
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 36.18%

Current $13.46
Target $18.33

Company Financials

FY18Y/Y Change
Revenue
19.6M
↑ 64.18%
Net Income
-9.6M
↑ 20.97%
Net Profit Margin
-48.69%
↑ 17.39%
FY19Y/Y Change
Revenue
33.9M
↑ 72.94%
Net Income
-18.3M
↑ 91.84%
Net Profit Margin
-54.01%
↓ 5.32%
FY20Y/Y Change
Revenue
78.7M
↑ 131.86%
Net Income
-32.7M
↑ 78.34%
Net Profit Margin
-41.54%
↑ 12.47%
FY21Y/Y Change
Revenue
222.6M
↑ 182.87%
Net Income
-275.5M
↑ 742.77%
Net Profit Margin
-123.77%
↓ 82.23%
FY22Y/Y Change
Revenue
237.3M
↑ 6.59%
Net Income
-37.3M
↓ 86.45%
Net Profit Margin
-15.73%
↑ 108.04%
FY23Y/Y Change
Revenue
233.3M
↓ 1.7%
Net Income
-99.6M
↑ 166.75%
Net Profit Margin
-42.69%
↓ 26.96%
Q3 FY22Q/Q Change
Revenue
60.5M
↓ 5.75%
Net Income
-5.3M
↓ 42.07%
Net Profit Margin
-8.79%
↑ 5.51%
Q4 FY22Q/Q Change
Revenue
60.4M
↓ 0.18%
Net Income
-9.4M
↑ 77.5%
Net Profit Margin
-15.63%
↓ 6.84%
Q1 FY23Q/Q Change
Revenue
62.8M
↑ 4.07%
Net Income
-5.6M
↓ 40.93%
Net Profit Margin
-8.87%
↑ 6.76%
Q2 FY23Q/Q Change
Revenue
57.0M
↓ 9.23%
Net Income
-18.4M
↑ 229.3%
Net Profit Margin
-32.19%
↓ 23.32%
Q3 FY23Q/Q Change
Revenue
56.2M
↓ 1.52%
Net Income
-13.3M
↓ 27.71%
Net Profit Margin
-23.63%
↑ 8.56%
Q4 FY23Q/Q Change
Revenue
57.3M
↑ 1.96%
Net Income
-62.4M
↑ 370.19%
Net Profit Margin
-108.96%
↓ 85.33%
FY18Y/Y Change
Total Assets
56.6M
↑ 179.41%
Total Liabilities
18.1M
↑ 660.24%
FY19Y/Y Change
Total Assets
135.9M
↑ 139.97%
Total Liabilities
9.6M
↓ 46.93%
FY20Y/Y Change
Total Assets
552.4M
↑ 306.56%
Total Liabilities
169.7M
↑ 1669.41%
FY21Y/Y Change
Total Assets
1.1B
↑ 101.48%
Total Liabilities
471.1M
↑ 177.62%
FY22Y/Y Change
Total Assets
1.0B
↓ 6.67%
Total Liabilities
482.9M
↑ 2.5%
FY23Y/Y Change
Total Assets
957.7M
↓ 7.8%
Total Liabilities
468.7M
↓ 2.94%
Q3 FY22Q/Q Change
Total Assets
1.0B
↓ 1.2%
Total Liabilities
478.1M
↑ 0.03%
Q4 FY22Q/Q Change
Total Assets
1.0B
↑ 0.48%
Total Liabilities
482.9M
↑ 1.01%
Q1 FY23Q/Q Change
Total Assets
1.0B
↑ 0.9%
Total Liabilities
487.6M
↑ 0.97%
Q2 FY23Q/Q Change
Total Assets
1.0B
↓ 1.67%
Total Liabilities
486.4M
↓ 0.25%
Q3 FY23Q/Q Change
Total Assets
1.0B
↓ 2.91%
Total Liabilities
463.1M
↓ 4.78%
Q4 FY23Q/Q Change
Total Assets
957.7M
↓ 4.29%
Total Liabilities
468.7M
↑ 1.21%
FY18Y/Y Change
Operating Cash Flow
-3.4M
↓ 6.44%
Investing Cash Flow
-12.9M
↑ 615.56%
Financing Cash Flow
38.5M
↑ 142.31%
FY19Y/Y Change
Operating Cash Flow
-1.3M
↓ 60.51%
Investing Cash Flow
-62.9M
↑ 388.4%
Financing Cash Flow
74.2M
↑ 92.44%
FY20Y/Y Change
Operating Cash Flow
-14.9M
↑ 1022.93%
Investing Cash Flow
-382.3M
↑ 507.55%
Financing Cash Flow
385.6M
↑ 420.0%
FY21Y/Y Change
Operating Cash Flow
8.1M
↓ 154.66%
Investing Cash Flow
-469.3M
↑ 22.74%
Financing Cash Flow
564.3M
↑ 46.36%
FY22Y/Y Change
Operating Cash Flow
-1.9M
↓ 122.78%
Investing Cash Flow
-59.7M
↓ 87.28%
Financing Cash Flow
-39.2M
↓ 106.94%
Q3 FY22Q/Q Change
Operating Cash Flow
982.0K
↓ 114.01%
Investing Cash Flow
-5.9M
↓ 90.83%
Financing Cash Flow
-459.0K
↓ 98.19%
Q4 FY22Q/Q Change
Operating Cash Flow
3.7M
↑ 272.1%
Investing Cash Flow
7.1M
↓ 221.47%
Financing Cash Flow
-5.3M
↑ 1055.99%
Q1 FY23Q/Q Change
Operating Cash Flow
2.8M
↓ 24.08%
Investing Cash Flow
-1.4M
↓ 119.41%
Financing Cash Flow
71.0K
↓ 101.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.1M
↓ 246.14%
Investing Cash Flow
33.7M
↓ 2535.14%
Financing Cash Flow
1.1M
↑ 1516.9%

Technicals Summary

Sell

Neutral

Buy

Cryoport, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cryoport, Inc.
Cryoport, Inc.
-29.9%
16.81%
-39.78%
-75.75%
-13.21%
Fedex Corporation
Fedex Corporation
-6.64%
6.97%
12.85%
-16.57%
43.69%
United Parcel Service, Inc.
United Parcel Service, Inc.
-1.86%
5.59%
-14.59%
-31.63%
46.67%
Zto Express (cayman) Inc.
Zto Express (cayman) Inc.
-0.29%
-13.8%
-27.97%
-36.03%
-36.03%
Expeditors Intl. Of Washington Inc.
Expeditors Intl. Of Washington Inc.
-3.45%
2.73%
1.13%
-2.68%
57.3%
Jb Hunt Transport Services Inc.
Jb Hunt Transport Services Inc.
-13.73%
-2.33%
-4.64%
-7.05%
75.84%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cryoport, Inc.
Cryoport, Inc.
NA
NA
0.0
-1.3
-0.19
-0.04
NA
9.45
Fedex Corporation
Fedex Corporation
15.36
15.36
0.96
17.8
0.17
0.05
0.02
107.18
United Parcel Service, Inc.
United Parcel Service, Inc.
21.22
21.22
1.79
8.13
0.32
0.08
0.04
19.75
Zto Express (cayman) Inc.
Zto Express (cayman) Inc.
14.47
14.47
1.5
1.66
0.15
0.08
0.03
74.31
Expeditors Intl. Of Washington Inc.
Expeditors Intl. Of Washington Inc.
22.53
22.53
1.57
4.7
0.27
0.12
0.01
16.61
Jb Hunt Transport Services Inc.
Jb Hunt Transport Services Inc.
26.09
26.09
2.04
6.43
0.17
0.07
0.01
40.37
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cryoport, Inc.
Cryoport, Inc.
Buy
$797.9M
-13.21%
NA
-42.69%
Fedex Corporation
Fedex Corporation
Buy
$65.5B
43.69%
15.36
5.02%
United Parcel Service, Inc.
United Parcel Service, Inc.
Hold
$125.1B
46.67%
21.22
6.6%
Zto Express (cayman) Inc.
Zto Express (cayman) Inc.
Buy
$17.0B
-36.03%
14.47
22.77%
Expeditors Intl. Of Washington Inc.
Expeditors Intl. Of Washington Inc.
Hold
$16.0B
57.3%
22.53
8.1%
Jb Hunt Transport Services Inc.
Jb Hunt Transport Services Inc.
Buy
$17.0B
75.84%
26.09
5.25%

Institutional Holdings

  • Brown Capital Management, LLC

    13.79%

  • Morgan Stanley - Brokerage Accounts

    8.52%

  • Vanguard Group Inc

    7.47%

  • BlackRock Inc

    7.29%

  • Cadian Capital Management LP

    7.07%

  • Impax Asset Management Group PLC

    5.31%

Corporate Announcements

  • Cryoport, Inc. Earnings

    Cryoport, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

cryoport delivers an innovative and complete outsourced frozen shipping solution for biological materials. this breakthrough combination replaces outdated dry ice shipping, virtually eliminates the risk of cell degradation and revolutionizes deep frozen logistics. we combine the technology of liquid nitrogen dry vapor shippers with the most advanced logistics management platform in the industry. when added with our logistics expertise, we provide a complete outsourced solution that advances deep-frozen shipping for the life science community. whether your business is bio-pharmaceuticals, clinical trials, research or reproductive medicine, you want to focus on your core mission. cryoport will help you transport life.

Organization
Cryoport, Inc.
Employees
1019
CEO
Mr. Jerrell W. Shelton
Industry
Process Industries

Discover More

FAQs